These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells. Cioce M; Rutigliano D; Puglielli A; Fazio VM Cancer Drug Resist; 2022; 5(3):814-828. PubMed ID: 36176750 [No Abstract] [Full Text] [Related]
11. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K; Serada S; Fujimoto M; Nomura S; Osaki T; Lee CM; Mizuguchi H; Takahashi T; Ripley B; Okumura M; Kawase I; Kishimoto T; Naka T Int J Cancer; 2011 Aug; 129(4):1005-17. PubMed ID: 20949562 [TBL] [Abstract][Full Text] [Related]
12. Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. Williams M; Cheng YY; Kirschner MB; Sarun KH; Schelch K; Winata P; McCaughan B; Kao S; Van Zandwijk N; Reid G Oncotarget; 2019 Jun; 10(41):4125-4138. PubMed ID: 31289611 [TBL] [Abstract][Full Text] [Related]
13. MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell. Doi T; Maniwa Y; Tanaka Y; Tane S; Hashimoto S; Ohno Y; Nishio W; Nishimura Y; Ohbayashi C; Okita Y; Hayashi Y; Yoshimura M Exp Mol Pathol; 2011 Feb; 90(1):91-6. PubMed ID: 20969861 [TBL] [Abstract][Full Text] [Related]
14. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243 [TBL] [Abstract][Full Text] [Related]
15. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249 [TBL] [Abstract][Full Text] [Related]
16. Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. Williams M; Cheng YY; Phimmachanh M; Winata P; van Zandwijk N; Reid G Cancer Drug Resist; 2019; 2(4):1193-1206. PubMed ID: 35582270 [No Abstract] [Full Text] [Related]
17. Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma. Amatya VJ; Mawas AS; Kushitani K; Mohi El-Din MM; Takeshima Y Int J Oncol; 2016 Apr; 48(4):1599-607. PubMed ID: 26820394 [TBL] [Abstract][Full Text] [Related]
18. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Mazieres J; You L; He B; Xu Z; Twogood S; Lee AY; Reguart N; Batra S; Mikami I; Jablons DM Int J Cancer; 2005 Nov; 117(2):326-32. PubMed ID: 15900580 [TBL] [Abstract][Full Text] [Related]
19. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen Suppresses the Growth of Malignant Pleural Mesothelioma Cells. Jennings CJ; Zainal N; Dahlan IM; Kay EW; Harvey BJ; Thomas W Anticancer Res; 2016 Nov; 36(11):5905-5913. PubMed ID: 27793915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]